Levi & Korsinsky Announces Investigation of Securities Claims Against Zevra Therapeutics, Inc. (ZVRA)

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Zevra Therapeutics, Inc. ("Zevra Therapeutics, Inc.") (NASDAQ:ZVRA) concerning potential violations of the federal securities laws.

July 24, 2026 brought a roughly 24% pre-market drop in Zevra Therapeutics after the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP") issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C.

The CHMP opinion was announced before regular trading and triggered an immediate selloff in Zevra shares. Financial news reports described the decline as the stock's worst single-day percentage loss in more than five years. The regulatory decision concerned arimoclomol, Zevra's lead product for Niemann-Pick disease type C.

Following the CHMP's negative opinion, Zevra announced that it intends to request a re-examination of the decision and would continue providing arimoclomol to eligible patients through its global Expanded Access Program pending further regulatory review.

If you suffered a loss on your Zevra Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP